Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Isenberg

Showing results (201-210 of 280) with videos related to

Pageof 28
Sort By:
Clinical Chemistry|March 22, 2008
Screening autoantibody profiles in systemic rheumatic disease with a diagnostic protein microarray that uses a filtration-assisted nanodot array luminometric immunoassay (NALIA)Jeffrey D McBride, Francis Guy Gabriel, John Fordham, et al.
The Lancet. Rheumatology|August 21, 2020
Disease-associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: patient stratification using a machine-learning approachGeorge A Robinson, Junjie Peng, Pierre Dönnes, et al.
Nature Immunology|March 30, 2024
Thioredoxin is a metabolic rheostat controlling regulatory B cellsHannah F Bradford, Thomas C R McDonnell, Alexander Stewart, et al.
International Immunology|March 2, 2010
Green tea polyphenol epigallocatechin gallate inhibits cell signaling by inducing SOCS1 gene expressionBarry J M Ripley, Minoru Fujimoto, Satoshi Serada, et al.
Ebiomedicine|February 28, 2021
Increased apolipoprotein-B:A1 ratio predicts cardiometabolic risk in patients with juvenile onset SLEGeorge A Robinson, Kirsty E Waddington, Leda Coelewij, et al.
The Journal of Rheumatology|April 3, 2010
Estimating indirect costs in primary Sjögren's syndromeSimon J Bowman, Yvan St Pierre, Nurhan Sutcliffe, et al.
ACR Open Rheumatology|November 29, 2019
Characterization of a Subset of Patients With Rheumatoid Arthritis for Whom Current Management Strategies are InadequateClaire M Bradford, Thomas McDonnell, Divya Raj, et al.
Rheumatology (Oxford, England)|April 2, 2013
Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-upDaniel J Wallace, Caroline Gordon, Vibeke Strand, et al.
Frontiers in Immunology|November 9, 2018
PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid SyndromeThomas C R McDonnell, Rohan Willis, Charis Pericleous, et al.
Arthritis and Rheumatism|December 30, 2009
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trialJoan T Merrill, C Michael Neuwelt, Daniel J Wallace, et al.
Pageof 28

Showing results (201-210 of 280) with videos related to

Sort By:
Pageof 28
Clinical Chemistry|March 22, 2008
Screening autoantibody profiles in systemic rheumatic disease with a diagnostic protein microarray that uses a filtration-assisted nanodot array luminometric immunoassay (NALIA)Jeffrey D McBride, Francis Guy Gabriel, John Fordham, et al.
The Lancet. Rheumatology|August 21, 2020
Disease-associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: patient stratification using a machine-learning approachGeorge A Robinson, Junjie Peng, Pierre Dönnes, et al.
Nature Immunology|March 30, 2024
Thioredoxin is a metabolic rheostat controlling regulatory B cellsHannah F Bradford, Thomas C R McDonnell, Alexander Stewart, et al.
International Immunology|March 2, 2010
Green tea polyphenol epigallocatechin gallate inhibits cell signaling by inducing SOCS1 gene expressionBarry J M Ripley, Minoru Fujimoto, Satoshi Serada, et al.
Ebiomedicine|February 28, 2021
Increased apolipoprotein-B:A1 ratio predicts cardiometabolic risk in patients with juvenile onset SLEGeorge A Robinson, Kirsty E Waddington, Leda Coelewij, et al.
The Journal of Rheumatology|April 3, 2010
Estimating indirect costs in primary Sjögren's syndromeSimon J Bowman, Yvan St Pierre, Nurhan Sutcliffe, et al.
ACR Open Rheumatology|November 29, 2019
Characterization of a Subset of Patients With Rheumatoid Arthritis for Whom Current Management Strategies are InadequateClaire M Bradford, Thomas McDonnell, Divya Raj, et al.
Rheumatology (Oxford, England)|April 2, 2013
Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-upDaniel J Wallace, Caroline Gordon, Vibeke Strand, et al.
Frontiers in Immunology|November 9, 2018
PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid SyndromeThomas C R McDonnell, Rohan Willis, Charis Pericleous, et al.
Arthritis and Rheumatism|December 30, 2009
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trialJoan T Merrill, C Michael Neuwelt, Daniel J Wallace, et al.
Pageof 28